📊 NTLA Key Takeaways
Is Intellia Therapeutics, Inc. (NTLA) a Good Investment?
Intellia is a pre-revenue CRISPR therapeutics company with severe cash burn (-$395.9M free cash flow) and negative profitability across all metrics, indicating the company is in early-stage development with substantial execution risk. While the company maintains adequate liquidity ($155.5M cash) relative to current burn rate, the fundamental business model is not yet profitable and depends entirely on successful clinical trial outcomes and regulatory approval.
Revenue is growing modestly, but the company remains deeply unprofitable with exceptionally negative operating and net margins and heavy cash burn. Liquidity is strong and there is no debt, yet cash on hand appears insufficient relative to annual operating outflows, pointing to likely near-term financing needs. On fundamentals alone, dilution risk and unclear path to profitability outweigh current revenue traction.
Why Buy Intellia Therapeutics, Inc. Stock? NTLA Key Strengths
- Strong balance sheet with $671.4M stockholders equity and minimal debt
- Adequate liquidity position with $155.5M cash and 5.08x current ratio providing runway
- Revenue growth of 16.9% YoY demonstrates some commercial traction despite pre-commercial stage
- Strong liquidity with 5.08x current ratio
- No long-term debt and sizable equity base
- Double-digit YoY revenue growth
NTLA Stock Risks: Intellia Therapeutics, Inc. Investment Risks
- Massive operating losses (-$441M) with operating margin of -651.7% indicate unsustainable business model dependent on R&D spending
- Severe negative free cash flow (-$395.9M) will deplete cash reserves within ~4 quarters at current burn rate without additional financing
- Clinical-stage biotech with existential risk tied to regulatory approval and clinical trial success; no approved products generating meaningful revenue
- Negative ROE (-61.5%) and ROA (-49.0%) reflect capital inefficiency and lack of profitability foundation
- Sustained large operating losses and >600% negative margins
- Severe negative operating cash flow and FCF implying short runway
- Small, potentially volatile collaboration-driven revenue base
Key Metrics to Watch
- Operating cash flow trend and cash runway (critical for survival)
- Clinical trial progress and regulatory milestones for lead CRISPR programs
- Revenue growth rate and pipeline advancement toward commercialization
- Dilution from future financing rounds and impact on capital structure
- Operating cash flow (burn rate)
- Cash & equivalents / months of runway
Intellia Therapeutics, Inc. (NTLA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.08x current ratio provides a solid financial cushion.
NTLA Profit Margin, ROE & Profitability Analysis
NTLA vs Healthcare Sector: How Intellia Therapeutics, Inc. Compares
How Intellia Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Intellia Therapeutics, Inc. Stock Overvalued? NTLA Valuation Analysis 2026
Based on fundamental analysis, Intellia Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Intellia Therapeutics, Inc. Balance Sheet: NTLA Debt, Cash & Liquidity
NTLA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Intellia Therapeutics, Inc.'s revenue has grown significantly by 17% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.42 indicates the company is currently unprofitable.
NTLA Revenue Growth, EPS Growth & YoY Performance
NTLA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9.1M | -$101.3M | $-0.92 |
| Q2 2025 | $7.0M | -$101.3M | $-0.98 |
| Q1 2025 | $16.6M | -$107.4M | $-1.10 |
| Q3 2024 | $9.1M | -$103.1M | $-1.34 |
| Q2 2024 | $7.0M | -$103.1M | $-1.40 |
| Q1 2024 | $12.6M | -$103.1M | $-1.12 |
| Q3 2023 | $12.0M | -$100.7M | $-1.38 |
| Q2 2023 | $13.6M | -$100.7M | $-1.33 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Intellia Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
NTLA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Intellia Therapeutics, Inc. (CIK: 0001652130)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NTLA
What is the AI rating for NTLA?
Intellia Therapeutics, Inc. (NTLA) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NTLA's key strengths?
Claude: Strong balance sheet with $671.4M stockholders equity and minimal debt. Adequate liquidity position with $155.5M cash and 5.08x current ratio providing runway. ChatGPT: Strong liquidity with 5.08x current ratio. No long-term debt and sizable equity base.
What are the risks of investing in NTLA?
Claude: Massive operating losses (-$441M) with operating margin of -651.7% indicate unsustainable business model dependent on R&D spending. Severe negative free cash flow (-$395.9M) will deplete cash reserves within ~4 quarters at current burn rate without additional financing. ChatGPT: Sustained large operating losses and >600% negative margins. Severe negative operating cash flow and FCF implying short runway.
What is NTLA's revenue and growth?
Intellia Therapeutics, Inc. reported revenue of $67.7M.
Does NTLA pay dividends?
Intellia Therapeutics, Inc. does not currently pay dividends.
Where can I find NTLA SEC filings?
Official SEC filings for Intellia Therapeutics, Inc. (CIK: 0001652130) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NTLA's EPS?
Intellia Therapeutics, Inc. has a diluted EPS of $-3.81.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NTLA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Intellia Therapeutics, Inc. has a SELL rating with 81% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NTLA stock overvalued or undervalued?
Valuation metrics for NTLA: ROE of -61.5% (sector avg: 15%), net margin of -609.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NTLA stock in 2026?
Our dual AI analysis gives Intellia Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NTLA's free cash flow?
Intellia Therapeutics, Inc.'s operating cash flow is $-394.7M, with capital expenditures of $1.1M. FCF margin is -585.0%.
How does NTLA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -609.9% (avg: 12%), ROE -61.5% (avg: 15%), current ratio 5.08 (avg: 2).